Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.55 |
| ▸ | GABRD | O14764 | 2/20 | 0.55 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.55 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.55 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.55 |
| ▸ | GABRE | P78334 | 2/20 | 0.55 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.55 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.55 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.55 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GPR3 | P46089 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20836229 | 0.93 | GABRP (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL12219442 | 0.82 | GABRP (0.69) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29380761 | 0.82 | ALDH1A1 (0.68) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1635466 | 0.82 | ALDH1A1 (0.68) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL12240744 | 0.80 | GABRP (0.67) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Carbazole SCHEMBL29011562 | 0.80 | ALDH1A1 (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL20836218 | 0.79 | CDK4 (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL20836236 | 0.79 | CDK4 (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL21757300 | 0.78 | AHR (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL22211849 | 0.78 | GABRP (0.64) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISIHARA YUJI | 2006-12-14 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| US-6534496-B1 | Prophylactic and/or therapeutic drug for obesity and obesity associated diseasestor diabetes with a reduced risk for central side effects and high universality in usage. Another object of the a lipolytic agent, or a prophylactic and/or | TAKEDA CHEMICAL INDUSTRIES, INC. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1118322-A1 | DRUGS FOR IMPROVING VESICAL EXCRETORY STRENGTH | Takeda Chemical Industries, Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
| EP-0885229-B1 | FUSED PYRROLO(2,3-C)CARBAZOLE-6-ONES WHICH POTENTIATE ACTIVITY OF GAMMA INTERFERON | CEPHALON INC (US) | 2000-08-02 | — | — | EP | disclosed |
| EP-0975624-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | Takeda Chemical Industries, Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
| EP-0885229-A1 | FUSED PYRROLO(2,3-C)CARBAZOLE-6-ONES WHICH POTENTIATE ACTIVITY OF GAMMA INTERFERON | CEPHALON, INC. (US) | 1998-12-23 | — | — | EP | disclosed |
| WO-1998046590-A1 | THERMOGENIC COMPOSITION AND BENZAZEPINE THERMOGENICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-10-22 | — | — | WO | disclosed |
| WO-1997031002-A1 | FUSED PYRROLO(2,3-C)CARBAZOLE-6-ONES WHICH POTENTIATE ACTIVITY OF GAMMA INTERFERON | CEPHALON, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
| US-5616724-A | FOR POTENTIATION OF HUMAN INTERFERON-GAMMA; IMMUNOLOGY | CEPHALON, INC. (US) | 1997-04-01 | — | — | US | disclosed |
| EP-0655451-A1 | Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | GABRP 2275/4885GABRD 1581/4885GABRA1 1491/4885 |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | GABRP 1957/4885GABRD 3266/4885GABRA1 2795/4885 |
| US-20020177593-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BPHL, BCHE | GABRP 1469/4885GABRD 2986/4885GABRA1 2683/4885 |
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | GABRP 35/4885GABRD 99/4885GABRA1 50/4885 |
| US-20060281725-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | GABRP 1951/4885GABRD 3180/4885GABRA1 2708/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | GABRP 1669/4885GABRD 1153/4885GABRA1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.